Right2Try does not sell Ivermectin, Fenbendazole, Mebendazole, Methylene Blue, Hydroxychloroquine, or any other supplements on this website or by Email.
Every change we make to Right2Try, newest first.
Marked the HCQ + palbociclib Phase Ib/II trial (NCT05953350) as Completed per ClinicalTrials.gov (record updated Nov 20, 2026).
Go to News & Trials →Added Research Square 2026 preprint: Ra-223 microspheres loaded with methylene blue slowed liver tumors in rats; not peer-reviewed.
Go to News & Trials →Added Polymers 2026 lab formulation study: fenbendazole-Soluplus solid dispersion dissolved much better; no cancer outcome tested.
Go to News & Trials →Added PLOS One 2026 lab study of mebendazole changing ENOX2/MMP2 and other cancer-related genes in eight cell lines.
Go to News & Trials →Added Pharmaceuticals 2026 study: computer screening flagged mebendazole for AML; active in lab cells and mice, but combos did not beat full-dose cytarabine in one model.
Go to News & Trials →Added Cureus 2026 retrospective study of 135 stage IV pancreatic cancer patients; the group that also got ivermectin and tamoxifen did not do better.
Go to News & Trials →Added J Pharm Sci 2026 lab study of hydroxychloroquine-loaded polydopamine nanoparticles in B16F10 melanoma cells; lab cells only.
Go to News & Trials →Added bioRxiv preprint on methylene blue blocking G3BP1 stress granules in pancreatic cancer cells and reducing early Kras-driven precancerous lesions in mice; not peer-reviewed, not tested in people.
Go to News & Trials →Added Neuro-Oncology 2025 SNO conference abstract (EXTH-110) on fenbendazole, papain and sodium selenite in brain tumor cell lines and an implantable scaffold in development; lab only.
Go to News & Trials →Added Artif Cells Nanomed Biotechnol 2026 lab study of inhalable ivermectin lipid-polymer nanoparticles in non-small cell lung cancer cell lines; lab cells only.
Go to News & Trials →Added Pharmaceutics 2026 mouse pharmacokinetic study of urea-based mebendazole prodrugs; absorption/exposure only, no cancer outcome tested.
Go to News & Trials →Added Cell Death Dis 2026 mouse study of ATC-37, an AUTOTAC built with a methylene blue–derived binder (not methylene blue itself) against mutant-p53 pancreatic tumors; animal only.
Go to News & Trials →Added J Mater Chem B 2026 preclinical study of an injectable gel releasing hydroxychloroquine plus a camptothecin polymer to curb tumor regrowth after surgery; animal models only.
Go to News & Trials →Added J Biochem Mol Toxicol 2026 lab study of hydroxychloroquine combined with empagliflozin in lung cancer cell lines; lab cells only.
Go to News & Trials →Added Acta Pharm Sin B 2026 mouse study of a methylene blue photodynamic nanoparticle paired with an immune booster; engineered nanoparticle, mice only.
Go to News & Trials →Added Drug Chem Toxicol 2026 lab study where fenbendazole reduced ovarian cancer cell survival more than non-cancerous ovarian cells; lab cells only.
Go to News & Trials →Added self-published 2026 Zenodo computer-modeling study (PBPK + network pharmacology) of ivermectin and fenbendazole across seven cancers, labeled as computer modeling and not peer-reviewed (doi 10.5281/zenodo.23759529).
Go to News & Trials →Added Cell Commun Signal 2026 preclinical study where hydroxychloroquine, by blocking autophagy, helped niraparib against resistant ovarian cancer in lab cells and mice.
Go to News & Trials →Added 2026 retrospective cohort study of hydroxychloroquine alongside steroids for checkpoint-inhibitor immune-related pneumonitis in melanoma patients (doi 10.1016/j.ejcskn.2026.101142, supportive care).
Go to News & Trials →Added Memorial Sloan Kettering Phase 2 recruiting trial testing weekly oral ivermectin plus standard prophylaxis to prevent daraxonrasib-induced skin rash in metastatic pancreatic cancer (NCT07895498, supportive care).
Go to News & Trials →Added Phase 1 results for hydroxychloroquine with gemcitabine, nab-paclitaxel and ipilimumab in metastatic pancreatic cancer (NCT04787991, J Immunother Cancer).
Go to News & Trials →Added Chem Sci 2026 lab study where thymoquinone kept methylene blue active and improved light-activated tumor cell killing (PMID 42819133).
Go to News & Trials →Added J Mater Sci Mater Med 2025 lab study where hydroxychloroquine increased the effect of folate-targeted doxorubicin nanoparticles in HT-29 colorectal cancer cells (PMID 41123713).
Go to News & Trials →Added registry results for the Phase 2 sorafenib plus hydroxychloroquine trial in advanced liver cancer (NCT03037437).
Go to News & Trials →Updated the MEK inhibitor + HCQ trial (NCT06229340) from Recruiting to Unknown status, per ClinicalTrials.gov (last known recruiting; no update since Jan 2024).
Go to News & Trials →Added BMC Pharmacol Toxicol 2026 lab study finding ivermectin weakened cisplatin in oral cancer cells (doi 10.1186/s40360-026-01198-w).
Go to News & Trials →Added Toxics 2026 rat study of ivermectin against atezolizumab ovarian toxicity (doi 10.3390/toxics14100876).
Go to News & Trials →Added World J Clin Cases 2026 case report of liver injury linked to self-dosed fenbendazole during immunotherapy (PMID 41608149).
Go to News & Trials →Added Angew Chem 2026 mouse study of a DNA nanorobot carrying methylene blue for photodynamic therapy (PMID 42799652).
Go to News & Trials →Added Biomaterials 2026 mouse study of an HCQ-loaded nanoparticle with radiotherapy in liver cancer (PMID 42810131).
Go to News & Trials →Added ACS Appl Polym Mater 2026 lab study of a gemcitabine plus HCQ polymer in pancreatic cancer cells (doi 10.1021/acsapm.6c02161).
Go to News & Trials →Added Cancer Gene Ther 2025 cell and mouse study of paricalcitol plus HCQ with 5-FU/oxaliplatin in pancreatic cancer (PMID 41015572).
Go to News & Trials →Added Int J Mol Sci 2025 lab study of hydroxychloroquine in gingival and tongue cancer cells (PMID 41303490).
Go to News & Trials →Added PLoS One 2025 lab study of mebendazole with gefitinib in lung and triple-negative breast cancer cells (PMID 41401147).
Go to News & Trials →Added J Adv Biotechnol Exp Ther 2026 lab study of ascorbic acid plus ivermectin in HeLa cervical cancer cells (doi 10.5455/jabet.2026.25).
Go to News & Trials →Added Drug Deliv Transl Res 2026 cell and mouse study of platelet-coated ivermectin nanocrystals in triple-negative breast cancer (PMID 41495333).
Go to News & Trials →Added J Biol Chem 2026 conference abstract on ivermectin, mebendazole and albendazole in colorectal cancer cells (doi 10.1016/j.jbc.2026.111939).
Go to News & Trials →Added Chem Biol Interact 2026 lab study of mebendazole in gastric cancer cells (PMID 41720422).
Go to News & Trials →Added J Vet Intern Med 2026 randomized placebo-controlled trial of vincristine with or without ivermectin in dogs with transmissible venereal tumor (PMID 41742510).
Go to News & Trials →Added The Oncologist 2026 published results of the Phase I trial of binimetinib plus hydroxychloroquine in previously treated metastatic pancreatic cancer (NCT04132505, PMID 41761573).
Go to News & Trials →Added Arabian Journal of Chemistry 2026 preclinical study of hydroxychloroquine/resveratrol nanoparticles in liver cancer cells (DOI 10.25259/ajc_346_2026).
Go to News & Trials →Added Frontiers in Oncology 2026 case report of metastatic melanoma with an initial response then progression during self-directed ivermectin and fenbendazole (PMID 42745863).
Go to News & Trials →Added Cell Physiol Biochem 2026 in vitro study of mebendazole combined with flutamide in prostate cancer cell lines (PMID 42675957).
Go to News & Trials →Added Cells 2026 preclinical study showing ivermectin reduces stress-induced Hsp70 synthesis and delays stress-granule clearance in neuroblastoma cells (PMID 42738916).
Go to News & Trials →News & Clinical Trials is now a compact table you can filter by compound, study type, phase, trial status and source, and sort newest or oldest first. Filtered views have shareable links.
Go to News & Trials →Updated the HCQ dormant breast cancer trial (NCT04841148) from Recruiting to Active, not recruiting, per ClinicalTrials.gov (Oct 16, 2026).
Go to News & Trials →Added Nature Communications 2026 preclinical study identifying mebendazole as an OCTN1 transporter inhibitor that suppressed cervical and lung cancer cell growth (PMID 42875455).
Go to News & Trials →Added 2026 Future Journal of Pharmaceutical Sciences meta-analysis finding that adding hydroxychloroquine to chemotherapy did not improve tumor response (7 studies, 383 patients).
Go to News & Trials →Added PLoS One 2026 preclinical study of mebendazole with gefitinib in gefitinib-resistant non-small cell lung cancer (PMID 42848765).
Go to News & Trials →Removed the mid-page overflow/max-height scroll container around the detox summary table so aids list straight on the page like supplements/binders details. Soft rounded cards and Edited styling unchanged.
Go to mRNA Detox →Detail blocks redesigned as soft rounded cream cards with shadows and clearer hierarchy. Fixed purple underlined Edited links in Safari (visited-link color) site-wide. Same medical content.
Go to mRNA Detox →Redesigned the How these aids may help section into real cards with nested panels, category badges, clearer hierarchy, and better mobile stacking. Same medical content.
Go to mRNA Detox →Restyled the mRNA Detox page to match the rest of the site: warm theme, category chips, summary table, and detail cards. Same content.
Go to mRNA Detox →New page listing every change to the site. The header now shows the date of the latest edit, and every page shows its own edited date. Both link here.
Go to Site Updates →The Hulscher et al. cohort (Anticancer Research, Jun 2026) was fully retracted in Oct 2026 for methodological and analytical problems. Added the retraction notice.
Go to News & Trials →Updated with the full Phase I result for HCQ + itraconazole: no large PSA drops, and Phase II was not pursued.
Go to News & Trials →Published Phase 1 (NCT02644291): mebendazole alone was well tolerated, but showed limited benefit on its own.
Go to News & Trials →Refreshed the HCQ + transarterial embolization trial for liver cancer (NCT05842174), now recruiting.
Go to News & Trials →Randomized Phase II adding hydroxychloroquine to chemotherapy in relapsed ovarian cancer. Result: no benefit.
Go to News & Trials →The 3-patient fenbendazole case series (Case Reports in Oncology, Jul 2025) was retracted in Jan 2026. Its entry now shows the retraction notice.
Go to News & Trials →Removed 184 more non-cancer sources after a manual review. 1,327 sources remain.
Go to Sources →Removed 111 sources that were not about cancer, found in a title-by-title audit of the source list.
Go to Sources →Sources now show as cards by compound, with Show more buttons and a jump menu.
Go to Sources →The category links at the top of Supplements now scroll to the right section of the table.
Go to Supplements →The Binders page got a new, cleaner layout.
Go to Binders →